BRPI0409263A - composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita - Google Patents

composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita

Info

Publication number
BRPI0409263A
BRPI0409263A BRPI0409263-5A BRPI0409263A BRPI0409263A BR PI0409263 A BRPI0409263 A BR PI0409263A BR PI0409263 A BRPI0409263 A BR PI0409263A BR PI0409263 A BRPI0409263 A BR PI0409263A
Authority
BR
Brazil
Prior art keywords
ikk
treating
patient
compound
pharmaceutical composition
Prior art date
Application number
BRPI0409263-5A
Other languages
English (en)
Inventor
Michael E Hepperle
Julie Fields Liu
Yingchun Ye
Raman Prakash
Alfredo Castro
Paul E Fleming
Francois Soucy
Robert S Murray
Jeremy D Little
Hormoz Mazdiyasni
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BRPI0409263A publication Critical patent/BRPI0409263A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO; COMPOSIçãO FARMACêUTICA; MéTODO PARA TRATAR UMA DOENçA MEDIADA POR IKK E MéTODO PARA INIBIR IKK EM UM PACIENTE QUE DELE NECESSITA". Esta invenção fornece compostos de beta-carbolina da fórmula I: onde o Anel A é um anel piridinila, pirimidinila, morfolinila, piperidinila, piperazinila, pirrolidinila, piranila, tetraidrofuranila, ciclo-hexila, ciclo-pentila ou tiomorfolinila, e R¬ 1¬, R¬ 2¬ e R¬ 3¬ são como descritos no relatório descritivo. Os compostos são inibidores de IKK-2, que são úteis para tratar doenças mediadas por IKK-2, tais como doenças inflamatórias e câncer.
BRPI0409263-5A 2003-04-09 2004-04-09 composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita BRPI0409263A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09
PCT/US2004/011080 WO2004092167A1 (en) 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease

Publications (1)

Publication Number Publication Date
BRPI0409263A true BRPI0409263A (pt) 2006-03-28

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409263-5A BRPI0409263A (pt) 2003-04-09 2004-04-09 composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita

Country Status (22)

Country Link
US (2) US7727985B2 (pt)
EP (1) EP1611134A1 (pt)
JP (1) JP2006522824A (pt)
KR (1) KR20060006031A (pt)
CN (1) CN1802375A (pt)
AU (1) AU2004230952A1 (pt)
BR (1) BRPI0409263A (pt)
CA (1) CA2521300A1 (pt)
CO (1) CO5700746A2 (pt)
CR (1) CR8042A (pt)
EA (1) EA009121B1 (pt)
EC (1) ECSP056145A (pt)
HR (1) HRP20050926A2 (pt)
MA (1) MA27837A1 (pt)
MX (1) MXPA05010793A (pt)
NI (1) NI200500174A (pt)
NO (1) NO20054598L (pt)
OA (1) OA13115A (pt)
RS (1) RS20050832A (pt)
TN (1) TNSN05257A1 (pt)
WO (1) WO2004092167A1 (pt)
ZA (1) ZA200508198B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.
JP2007532582A (ja) * 2004-04-09 2007-11-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置に有用なβ−カルボリン
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
WO2007106884A2 (en) * 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US20100098641A1 (en) * 2006-12-13 2010-04-22 William Baker Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
US20090131422A1 (en) * 2007-10-23 2009-05-21 Millennium Pharmaceuticals, Inc. Salts of an IKK inhibitor
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
JP5892791B2 (ja) 2008-05-14 2016-03-23 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 適応免疫における免疫調節物質の効果をモニターするための方法およびキット
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
US8748428B2 (en) 2010-03-30 2014-06-10 Novartis Ag Use of a PKC inhibitor
JP6049216B2 (ja) * 2011-03-28 2016-12-21 エスジェイティー モレキュラー リサーチ，エス．エル． メタボリック症候群の処置のための化合物
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4925099A (en) * 1998-08-12 2000-03-06 Pfizer Products Inc. Tace inhibitors
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
MEP28108A (en) * 2000-03-15 2010-10-10 Sanofi Aventis Deutschland Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.

Also Published As

Publication number Publication date
NO20054598D0 (no) 2005-10-06
ZA200508198B (en) 2007-01-31
NO20054598L (no) 2005-10-27
JP2006522824A (ja) 2006-10-05
RS20050832A (sr) 2007-12-31
MXPA05010793A (es) 2005-12-05
MA27837A1 (fr) 2006-04-03
EA009121B1 (ru) 2007-10-26
ECSP056145A (es) 2006-04-19
KR20060006031A (ko) 2006-01-18
WO2004092167A8 (en) 2006-01-05
CA2521300A1 (en) 2004-10-28
TNSN05257A1 (en) 2007-07-10
AU2004230952A1 (en) 2004-10-28
EP1611134A1 (en) 2006-01-04
CO5700746A2 (es) 2006-11-30
CN1802375A (zh) 2006-07-12
EA200501584A1 (ru) 2006-06-30
NI200500174A (es) 2006-04-17
OA13115A (en) 2006-11-10
HRP20050926A2 (en) 2006-06-30
US20040235839A1 (en) 2004-11-25
CR8042A (es) 2006-05-30
US20100093713A1 (en) 2010-04-15
WO2004092167A1 (en) 2004-10-28
US7727985B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
TW200714604A (en) Substituted heterocycles and the uses thereof
EA200501584A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
SE0300456D0 (sv) Novel compounds
EA200601884A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
DE60329326D1 (de) Tace inhibitoren
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
BRPI0415355A (pt) triarilimidazóis
DE50308230D1 (de) Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
BR0210407A (pt) Composto, composição farmacêutica, uso de um composto e método de tratamento de um distúrbio ou de uma doença de corpo animal vivo, incluindo um humano
NO20063331L (no) Nikotinacetylcholinreseptorligander
UA84016C2 (ru) Бета-карболины, полезные для лечения воспалительных заболеваний, фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 471/04, 265/30; A61K 31/437; A61P 35/00

Ipc: C07D 471/04 (2011.01), C07D 265/30 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.